Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Phase 2
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00951405
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 21
- Registration Number
- NCT00943501
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
Phase 2
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT00936403
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Cambridge, United Kingdom
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 121
- Registration Number
- NCT00934063
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin
Phase 1
Completed
- Conditions
- HealthyAdult Growth Hormone DeficiencyGrowth Hormone Disorder
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00931476
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Honolulu, Hawaii, United States
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia B
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8
- Registration Number
- NCT00922792
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Korea
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1932
- Registration Number
- NCT00918151
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
Phase 2
Completed
- Conditions
- Cardiac Surgery Requiring Cardiopulmonary BypassAcquired Bleeding Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 479
- Registration Number
- NCT00914589
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 457
- Registration Number
- NCT00909480
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Pathumthani, Thailand
A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: Oral Glucose Tolerance Test (OGTT)Other: Euglycaemic hyperinsulinaemic clamp
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 271
- Registration Number
- NCT00897169
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath